NEW YORK, June 19, 2014 /PRNewswire/ -- Attorney
Advertising -- Bronstein, Gewirtz & Grossman, LLC is
investigating potential claims on behalf of purchasers of the
securities of Northwest Biotherapeutics, Inc. ("Northwest
Biotherapeutics" or the "Company") (NasdaqCM: NWBO). The
investigation focuses on whether the Company and its executives
violated federal securities laws.
On June 19, 2014, shares of the
Company fell during intraday trading $2.06 or 22.97% to trade at $6.91 after a report published by the website
TheStreet.com states that, "The prestigious MD Anderson
Cancer Center issued a stern rebuke to Northwest
Biotherapeutics (NWBO) for making promotional,
unjustified claims about results from an ongoing clinical
trial of an experimental cancer vaccine known as
DCVax-Direct." MD Anderson Cancer Center is running the
DCVax-Direct clinical trial with funding from Northwest
Biotherapeutics.
If you are aware of any facts relating to this investigation, or
purchased shares of Northwest Biotherapeutics, you can assist this
investigation by contacting either Edward
N. Gewirtz or his Investor Relations Coordinator
Eitan Kimelman of Bronstein, Gewirtz
& Grossman, LLC at 212-697-6484 or via email info@bgandg.com.
Those who inquire by e-mail are encouraged to include their mailing
address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Edward N. Gewirtz or Eitan Kimelman 212-697-6484
info@bgandg.com
SOURCE Bronstein, Gewirtz & Grossman, LLC